Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus

Abstract

Introduction: Quick release bromocriptine (BROM-QR), currently approved for glycemic control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus (T2DM). This study evaluates the effect of BROM-QR on homocysteine (HOMC) and high sensitive C-reactive protein (hs-CRP), the biochemical markers of coronary atherosclerosis/inflammation, in patients with uncontrolled T2DM. Methods: In this non-randomized, before-and-after clinical trial, patients with uncontrolled T2DM on stable doses of two oral hypoglycemic agents received BROM-QR for 6 months. The change in serum concentrations of HOMC was the primary endpoint. Anthropometric measurements such as body mass index (BMI) and waist circumference were measured at the baseline and at the completion of treatment along with fasting plasma glucose (FPG), HbA1c, total cholesterol, triglyceride, creatinine and hs-CRP. Multivariate regression analysis was performed to identify factors associated with changes in the levels of HOMC. Results: In 64 patients (46 completed 6 months of treatment), age was 55 +/- 7 years and the duration of T2DM was 8.0 +/- 4.4 years. On enrollment, mean HbA1c, FPG, hs-CRP and HOMC levels were 9.0 +/- 1.3 percent, 184 +/- 42 mg/dL, 3.8 +/- 3.4 mg/dl and 10.8 +/- 6.2 micromole/L; respectively. Mean decrease of 0.7 +/- 1.1 percent for HbA1c (P = 0.001) and 22 +/- 44 mg/dL for FPG was observed (P = 0.002). HOMC levels decreased to 8.5 +/- 5.2 micromole/L (P = 0.011) while hs-CRP levels remained unchanged at 3.7 +/- 2.9 mg/dL (P = 0.835). Conclusion: While HOMC and HbA1c levels decreased significantly after 6 months of treatment with BROM-QR in patients with T2DM, serum levels of hs-CRP, total cholesterol and triglyceride did not significantly change.